CJC-1295 with DAC (5mg)
Technische Spezifikationen
| Reinheit (HPLC) | ≥99% (HPLC) |
| CAS-Nummer | 863288-34-0 |
| Form | White lyophilized powder |
| Lagerung | -20°C |
| Sequenz | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Molekulargewicht | 3,367.89 g/mol |
| Salzform | Acetate |
| Löslichkeit | Soluble in water |
CJC-1295 with DAC (5mg)
EUR-Listenpreis · HU, SK, CZ, PL
- Eurozone (EUR)60,29 EUR
- Ungarn (HU)60,29 EUR≈ 24 116 Ft
- Slowakei (SK)60,29 EUR
- Tschechien (CZ)60,29 EUR≈ 1 507 Kč
- Polen (PL)60,29 EUR≈ 256,23 zł
Gleicher EUR-Listenpreis für Lieferung nach Ungarn, Slowakei, Tschechien und Polen. Abrechnung in EUR.
HUF/CZK/PLN sind indikativ aus EUR umgerechnet; die Slowakei nutzt EUR. Kurse annähernd. Abrechnung in EUR.
CJC-1295 mit DAC — albuminbindender Drug Affinity Complex für verlängerte Halbwertszeit im pharmakokinetischen Vergleich mit der No-DAC-Variante. Nur RUO — ausschließlich für Laborforschung; nicht zum menschlichen Verzehr.
Ausschließlich für Laborforschung.
Nicht für den menschlichen Verzehr, tierärztliche oder diagnostische Zwecke.
From the Peptide Explorer
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Key Mechanisms
- ›GHRH receptor agonism
- ›Pulsatile GH release promotion
- ›Synergy with GHSR agonists (ipamorelin)
- ›Somatostatin-sensitive (preserves feedback)
- ›Enhanced half-life via amino acid substitutions
Primary Research Areas
- ›GH axis physiology
- ›Pulsatile GH release
- ›Body composition
- ›Combined secretagogue protocols
Key Research Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Overview
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Origin: Modified analog of Growth Hormone Releasing Hormone (GHRH) 1-29
Mechanism of Action
- GHRH receptor agonism
- Pulsatile GH release promotion
- Synergy with GHSR agonists (ipamorelin)
- Somatostatin-sensitive (preserves feedback)
- Enhanced half-life via amino acid substitutions
Primary Research Areas
- GH axis physiology
- Pulsatile GH release
- Body composition
- Combined secretagogue protocols
Key Published Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
CJC-1295 with DAC (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Forschungsspezifikationen
Synthesized for strict analytical consistency. Verified via HPLC/MS.Qualitätsstandards ansehen →
Handhabung & Lagerung
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water